Effects of Sunitinib in Combination with Octreotide LAR for Patients with Advanced Pancreatic Neuroendocrine Tumor which Failed Sunitinib or Octreotide LAR Alone
#846
Introduction:
Aim(s): To observe the efficacy and side effects of sunitinib in combination with octreotide LAR for patients with advanced pancreatic neuroendocrine tumor (pNET) which failed Sunitinib or octreotide LAR alone.
Materials and methods: From May 2010 to October 2013, three patients got sunitinib 37.5mg/d (Group A) and two patients got octreotide LAR 20mg/4w (Group B), respectively. After progression on single agent, the five patients got combination therapy of the two drugs. The mean age was 53.2 years(48-62 years). Four patients were male and one female. Two had G1 pNET, three had G2. Three patients had their primary tumor resected. Somatostatin receptor scintigraphy of all patients revealed tracer-uptake lesions.
Conference: 11th Annual ENETSConcerence (2014)
Presenting Author:
Authors: Ying H, Cheng Y, Sun Z, Xue H, Meng C,
Keywords: pNET, Sunitinib, octreotide LAR, combination, efficacy,
To read the full abstract, please log into your ENETS Member account.